Skip to search formSkip to main contentSkip to account menu

vardenafil

Known as: Vardenafilum, Vardénafil, 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-F][1,2,4]triazin-4(1H)-one 
A benzenesulfonamide derivative and phosphodiesterase type 5 (PDE5) inhibitor with vasodilatory activity. Vardenafil selectively inhibits PDE5, thus… 
National Institutes of Health

Related topics

Related topics

9 relations

Narrower (3)

LevitraVardenafil hydrochlorideVardenafil hydrochloride trihydrate
NitratesNitroglycerinVardenafil:MCnc:Pt:Bld:QnVardenafil:MCnc:Pt:Ser/Plas:Qn

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
Highly Cited
2013
Highly Cited
2013
PDE5 inhibitors blunt inflammation in human BPH: A potential mechanism of action for PDE5 inhibitors in LUTS
Metabolic syndrome (MetS) and benign prostate hyperplasia (BPH)/low urinary tract symptoms (LUTS) are often comorbid. Chronic… 
Highly Cited
2007
Highly Cited
2007
Chronic daily tadalafil prevents the corporal fibrosis and veno‐occlusive dysfunction that occurs after cavernosal nerve resection
Associate Editor 
Highly Cited
2006
Highly Cited
2006
Simultaneous determination of synthetic phosphodiesterase-5 inhibitors found in a dietary supplement and pre-mixed bulk powders for dietary supplements using high-performance liquid chromatography…
Review
2004
Review
2004
Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
Highly Cited
2003
Highly Cited
2003
Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells.
Type 4 phosphodiesterase (PDE4) inhibitors reportedly induce apoptosis in chronic lymphocytic leukemia (CLL) cells. Following… 
Review
2002
Review
2002
Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
Since introduction of the PDE-5 inhibitor sildenafil 4 years ago, there has been a fundamental change in the treatment of… 
Highly Cited
2001
Highly Cited
2001
Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study
Abstract The pharmacodynamic effect on penile rigidity and tumescence and the pharmacokinetic properties of single oral doses of… 
Highly Cited
2001
Highly Cited
2001
The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil
We investigated the potency and the selectivity profile of vardenafil on phosphodiesterase (PDEs) enzymes, its ability to modify… 
Review
2001
Review
2001
Oral drug therapy for erectile dysfunction.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)